RUNX1 and acute myeloid leukemia: For example, Fenouille et al. [64] reported that an ATP-buffering mitochondrial creatine kinase (CKMT1A) is tightly associated with MECOM/EVI1 expression in AML, and the administration of cyclocreatine, a CKMT1A inhibitor, can dramatically reduce the viability of MECOM/EVI1-expressing AML cells.